INTELGENX TECHNOLOGIES CORP.

(IGXT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Business Summary
Logo IntelGenx Technologies Corp.
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company is focused on the development and manufacturing of pharmaceutical films. The Company's pharmaceutical film technologies include VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, which allows pharmaceutical products that address unmet medical needs. The Company's product pipeline offers various benefits to patients and physicians for many therapeutic conditions. Its VersaFilm research and development (R&D) services are based on a versatile drug delivery platform technology that enables the development of oral thin films exhibiting improved product performance. Its VetaFilm R&D services and veterinary oral films provide various market opportunities for improved drug delivery for companion animals. Its product portfolio includes RIZAPORT (Rizatriptan), EXORDIA (Tadalafil), Loxapine, Montelukast, Buprenorphine / Naloxone, and Dronabinol AdVersa (Dronabinol).
Sales per Business
20202021Delta
Pharmaceutical Products1.54100%1.54100% -0.58%
USD in Million
Sales per region
20202021Delta
Europe0.8051.5%1.0266.6% +28.68%
Canada0.7145.9%0.2617.1% -62.85%
United States0.042.7%0.2516.2% +507.32%
USD in Million
Managers
Name Title Age Since
Horst G. Zerbe, Dr. Chairman & Chief Executive Officer 74 2019
André Godin President & Chief Financial Officer 58 2019
Nadine Paiement Vice President-Research & Development 44 2016
Rodolphe Obeid, Dr. Chief Operating Officer 41 -
Stephen John Kilmer Investor Relations Contact - -
Ingrid Zerbe Secretary 66 2015
Dana Matzen, Dr. Vice President-Business & Corporate Development 43 2016
Tommy Kenny Vice President-Legal Affairs & General Counsel - 2021
Members of the board
Name Title Age Since
Horst G. Zerbe, Dr. Chairman & Chief Executive Officer 74 2019
Bernd Josef Melchers Independent Director 69 2011
J. Bernard Boudreau Independent Director 76 2012
Mark H. Nawacki Independent Director 52 2016
Monika Trzcinska, Dr. Independent Director - 2022
Clemens Mayr Director 52 2015
Srinivas G. Rao, Dr. Director 52 2021
Frank Stegert Director 39 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 154,691,290 115,677,271 74.8% 0 0.0% 74.8%
Shareholders
NameEquities%
Atai Life Sciences N.V. 37,300,000 24.1%
Ingrid Zerbe 319,094 0.21%
André Godin 200,171 0.13%
J. Bernard Boudreau 150,000 0.097%
Bernd Josef Melchers 120,000 0.078%
Tommy Kenny 86,000 0.056%
John S. Marinucci 75,000 0.048%
Dana Matzen 60,000 0.039%
DAFNA Capital Management LLC 43,480 0.028%
Columbia Management Investment Advisers LLC 20,000 0.013%
Brand Portfolio
In partnership withAllbrands.markets
More brands of IntelGenx Technologies Corp.